A Comprehensive Monograph on Pyrimethamine (DB00205)

Introduction and Drug Profile

Overview of Pyrimethamine: Class, Primary Use, and Clinical Significance

Pyrimethamine is a synthetic diaminopyrimidine derivative, pharmacologically classified as an antiprotozoal agent and a folic acid antagonist.[1] Its primary clinical application is in the treatment of toxoplasmosis, an infection caused by the protozoan parasite

Toxoplasma gondii. This therapeutic role is particularly critical in immunocompromised patient populations, such as individuals with Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS), where toxoplasmic encephalitis represents a life-threatening opportunistic infection.[4] Historically, pyrimethamine was a cornerstone in the global management of malaria, although its utility for this indication has been significantly curtailed by the widespread emergence of drug-resistant

Plasmodium strains.[6]

The enduring clinical importance of pyrimethamine is underscored by its inclusion on the World Health Organization's List of Essential Medicines, a designation reserved for medications considered most effective and safe to meet the most important needs in a health system.[9] Despite its long history of use and established efficacy, the drug has a dual identity in modern medicine. It is both a vital, often life-saving, therapeutic agent for a serious parasitic disease and, simultaneously, a prominent symbol of the complex and often contentious issues surrounding pharmaceutical pricing, access, and market ethics in the 21st century. This report provides a comprehensive monograph on pyrimethamine, detailing its chemical properties, pharmacology, clinical applications, safety profile, and the socio-economic context that has defined its recent history.

Chemical Identity and Physicochemical Properties

A thorough understanding of pyrimethamine's pharmacology and formulation begins with its fundamental chemical and physical characteristics. It is a well-defined small molecule with a distinct structure that dictates its biological activity.

Pyrimethamine is chemically identified as 5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidinediamine.[11] It is most commonly known by its generic name, pyrimethamine, and has been marketed under several brand names, most notably Daraprim for the single-agent formulation and Fansidar when in a fixed-dose combination with sulfadoxine.[5] Other synonyms include Chloridine.[12] Its unique identity is cataloged under several international numbering systems, including DrugBank Accession Number DB00205, Chemical Abstracts Service (CAS) Number 58-14-0, and MDL Number MFCD00057350.[11]

Structurally, pyrimethamine belongs to the chemical class of 6-membered heterocyclic compounds, specifically monocyclic pyrimidines.[1] Its molecular formula is

C12​H13​ClN4​, corresponding to a molecular weight of 248.71 g/mol.[3] The physical properties of the compound are consistent and well-documented. It presents as an odorless and tasteless, white to almost white crystalline powder or solid.[1] The melting point is generally reported in the range of 233–234 °C, with some analyses indicating a range up to 243.0 °C.[1] Its solubility profile is characterized by being practically insoluble in water, with an aqueous solubility of approximately 10 mg/L, and slightly soluble in solvents such as ethanol and dilute hydrochloric acid.[3] The octanol-water partition coefficient (LogP) is 2.69, indicating moderate lipophilicity, which facilitates its passage across biological membranes.[3]

Property	Value	Source(s)
Chemical Name	5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidinediamine	11
DrugBank ID	DB00205	User Query
CAS Number	58-14-0	11
Molecular Formula	C12​H13​ClN4​	3
Molecular Weight	248.71 g/mol	3
Appearance	White to almost white, odorless, tasteless crystalline powder	1
Melting Point	233–243 °C	1
Aqueous Solubility	Practically insoluble (~10 mg/L)	3
LogP	2.69	3
Chemical Class	Diaminopyrimidine	12

Preclinical and Clinical Pharmacology

Mechanism of Action: Inhibition of Dihydrofolate Reductase

The therapeutic effect of pyrimethamine is derived from its function as a potent and selective inhibitor of the enzyme dihydrofolate reductase (DHFR).[1] DHFR is a critical enzyme in the folate biosynthesis pathway, responsible for catalyzing the reduction of dihydrofolic acid to tetrahydrofolic acid (also known as folinic acid). Tetrahydrofolate and its derivatives are essential cofactors that act as carriers of one-carbon units in a variety of metabolic reactions. These reactions are fundamental for the de novo synthesis of nucleic acid precursors—specifically purines (adenine, guanine) and the pyrimidine thymidylate—as well as certain amino acids like methionine.[4] By competitively binding to the active site of DHFR with high affinity, pyrimethamine effectively blocks the production of tetrahydrofolate. This blockade halts DNA synthesis and, consequently, arrests cell division and parasite replication, ultimately leading to cell death.[4]

A cornerstone of pyrimethamine's clinical utility is its selective toxicity. The drug exhibits a significantly higher affinity for the DHFR enzyme found in protozoan parasites compared to the analogous enzyme in mammalian hosts. The inhibitory effect against human DHFR is approximately 1,000 times weaker than its effect on the protozoal enzyme.[1] This differential affinity creates a therapeutic window, allowing for the targeting of the parasite's metabolic machinery while minimizing disruption to the host's cellular processes at standard therapeutic doses. However, this selectivity is not absolute. At the high doses required for the treatment of toxoplasmosis, pyrimethamine can inhibit human DHFR to a clinically significant degree, leading to the characteristic dose-limiting toxicities associated with the drug, primarily bone marrow suppression.[2]

The antiprotozoal activity of pyrimethamine is markedly potentiated when it is co-administered with a sulfonamide, such as sulfadoxine or sulfadiazine. This synergistic interaction is a classic example of sequential enzymatic blockade. While pyrimethamine inhibits DHFR, sulfonamides act on an earlier, distinct step in the same metabolic pathway by inhibiting the enzyme dihydropteroate synthase (DHPS).[14] DHPS is responsible for the synthesis of dihydrofolic acid's precursor, dihydropteroate. By blocking two sequential steps in a vital metabolic pathway, the combination produces a much more profound and durable inhibition of folate synthesis than either agent alone. This synergistic approach not only enhances therapeutic efficacy but is also a fundamental strategy to delay the development of drug resistance, as a parasite would need to simultaneously acquire mutations in two separate genes to overcome the blockade.[7]

Pharmacodynamics: Antiprotozoal Activity and Resistance Mechanisms

Pyrimethamine exhibits a targeted spectrum of activity against several protozoan parasites of medical importance. It possesses potent blood schizonticidal activity against the asexual erythrocytic stages of all four human Plasmodium species: P. falciparum, P. vivax, P. ovale, and P. malariae.[2] In addition to killing the parasites within red blood cells, it also has some tissue schizonticidal activity and arrests the process of sporogony within the mosquito vector, which helps to reduce the transmission of malaria within a community.[2] Its activity against

Toxoplasma gondii is particularly high, forming the basis for its primary modern indication.[2]

Despite its initial effectiveness, the clinical utility of pyrimethamine, especially in malaria, has been severely compromised by the emergence and spread of drug resistance. The primary mechanism of resistance involves genetic mutations in the parasite's dhfr gene.[10] These point mutations, occurring at key residues within the enzyme's active site, alter its three-dimensional structure. This structural change reduces the binding affinity of pyrimethamine for the enzyme, sometimes by several hundred-fold, while preserving the enzyme's ability to bind its natural substrate, dihydrofolate.[12] Consequently, the parasite can continue its folate synthesis pathway even in the presence of the drug. High-grade resistance can emerge from a single-step mutation, which cannot be overcome by simply increasing the drug dosage.[12] The rapid selection and spread of these resistant strains, particularly when pyrimethamine was used as a monotherapy, was a pivotal lesson in anti-infective chemotherapy. This historical failure directly informed the now-standard practice of using pyrimethamine only as part of a combination regimen, a principle that has been broadly applied across infectious diseases to combat the evolution of drug resistance.

Pharmacokinetics: A Detailed Analysis of Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of pyrimethamine is characterized by good oral absorption, extensive distribution, and a remarkably long elimination half-life, all of which have significant clinical implications for its dosing and safety.

Absorption: Pyrimethamine is well absorbed following oral administration. Peak plasma concentrations (Cmax​) are typically achieved within 2 to 6 hours (Tmax​) after ingestion.[4]

Distribution: After absorption, the drug is widely distributed throughout the body, with notable accumulation in the kidneys, liver, spleen, and lungs.[18] It is highly bound to plasma proteins, with estimates of the bound fraction ranging from 87% to 90%.[4] This high degree of protein binding influences its distribution and availability of free, active drug. The apparent volume of distribution (

Vd​) is moderate to large, indicating significant tissue penetration. Studies have reported values of approximately 3.1 to 3.7 L/kg in adults, while pediatric studies have shown that Vd​ is related to body weight, with a typical value of 36 L for an 11 kg child.[19] Of critical clinical importance, pyrimethamine readily crosses the placental barrier and is also excreted into breast milk.[15] This property necessitates careful risk-benefit assessment when considering its use during pregnancy and lactation.

Metabolism: Pyrimethamine undergoes hepatic metabolism, where it is converted into several metabolites that have not been fully identified or characterized.[4]

Excretion: The parent drug and its metabolites are eliminated primarily through the kidneys.[15] A defining feature of pyrimethamine's pharmacokinetics is its very slow elimination, reflected in a long terminal elimination half-life (

t1/2​). The mean half-life is consistently reported to be approximately 96 to 100 hours, or about 4 days.[4] This long half-life is advantageous for prophylactic regimens, as it allows for convenient weekly dosing. However, it also presents a significant clinical challenge. In the event of a severe adverse reaction, the drug cannot be rapidly cleared from the body, and significant plasma concentrations will persist for weeks, potentially prolonging and exacerbating the toxicity. This pharmacokinetic property directly heightens the drug's risk profile and underscores the clinical imperative to discontinue the medication immediately at the first indication of a serious adverse event. Total body clearance (CL) is influenced by body weight, with a typical value in children of 5.50 L/day for an 11 kg subject.[19]

Pharmacokinetics in Special Populations:

The disposition of pyrimethamine can be significantly altered in certain populations. In pregnant women, complex physiological changes can lead to an 18% decrease in the clearance of pyrimethamine, resulting in greater overall drug exposure compared to non-pregnant women.21 This finding is crucial for understanding the safety and efficacy of intermittent preventive therapy during pregnancy (IPTp). In pediatric patients, pharmacokinetic parameters such as clearance and volume of distribution are strongly correlated with body weight and are best described using allometric scaling models.19

The pharmacology of pyrimethamine is directly and inextricably linked to its clinical use and management. The mechanism of folate antagonism is not merely a biochemical detail; it is the direct cause of the drug's principal dose-limiting toxicity—myelosuppression. The high doses required to treat toxoplasmosis can overwhelm the selective affinity for the parasitic enzyme, leading to inhibition of host DHFR and a subsequent deficiency in functional folate. This manifests clinically as megaloblastic anemia, leukopenia, and thrombocytopenia. This direct, on-target causal link necessitates a specific and mandatory clinical intervention: the co-administration of leucovorin (folinic acid).[2] Leucovorin is a reduced form of folic acid that is downstream of the DHFR-catalyzed step. Human cells can readily transport and utilize leucovorin, thereby bypassing the enzymatic block and restoring normal hematopoiesis. Critically, protozoan parasites like

Toxoplasma lack the transport mechanism for leucovorin and cannot utilize it.[22] This differential capability allows leucovorin to function as a "rescue" agent, selectively protecting the host from the drug's toxicity without compromising its antiparasitic efficacy. Therefore, leucovorin is not an optional adjunct but an essential component of high-dose pyrimethamine therapy, creating a complex but rational therapeutic triad of pyrimethamine, a sulfonamide, and leucovorin.

Parameter	Value / Description	Source(s)
Bioavailability	Well absorbed orally	4
Time to Peak (Tmax​)	2–6 hours	4
Plasma Protein Binding	~87–90%	4
Metabolism	Hepatic	4
Volume of Distribution (Vd​)	3.1–3.7 L/kg (adults); 36 L (for 11 kg child)	19
Route of Elimination	Renal	15
Elimination Half-life (t1/2​)	~96–100 hours	4
Clearance (CL)	5.50 L/day (for 11 kg child)	19

Therapeutic Applications and Clinical Evidence

Primary Indication: Management of Toxoplasmosis

The primary and most critical contemporary use of pyrimethamine is in the treatment of toxoplasmosis. The U.S. Food and Drug Administration (FDA) has approved pyrimethamine for this indication, specifically for use in conjunction with a sulfonamide, with which it acts synergistically.[6] This combination therapy is the globally recognized standard of care and regimen of choice for managing infections caused by

Toxoplasma gondii.[7]

Pyrimethamine-based therapy is indispensable across several distinct clinical scenarios:

• Toxoplasmic Encephalitis (TE) in Immunocompromised Patients: In individuals with compromised immune systems, particularly those with advanced HIV/AIDS, TE is a severe and often fatal opportunistic infection. Pyrimethamine, combined with sulfadiazine and supplemented with leucovorin rescue, is the first-line therapy for both the acute treatment of TE and for long-term secondary prophylaxis (chronic maintenance therapy) to prevent relapse.[6]
• Congenital Toxoplasmosis: When a pregnant woman acquires a primary Toxoplasma infection, the parasite can be transmitted to the fetus, potentially causing severe neurological damage, chorioretinitis, and other systemic abnormalities. The combination of pyrimethamine, sulfadiazine, and leucovorin is the recommended treatment for congenitally infected neonates and infants, administered over a year-long course to mitigate long-term sequelae.[7]
• Ocular Toxoplasmosis: T. gondii is a leading cause of infectious posterior uveitis. Pyrimethamine-based combination therapy is used to treat active chorioretinitis, reducing inflammation and preventing vision-threatening scarring.[2]
• Primary Prophylaxis: In certain high-risk patient groups, such as HIV-positive individuals with CD4+ T-cell counts below 100 cells/µL and positive Toxoplasma serology, prophylactic pyrimethamine (often with dapsone) is recommended to prevent the first episode of TE.[6]

The clinical utility of pyrimethamine has undergone a significant transformation over its history. Originally developed and widely deployed as a broad-spectrum antimalarial, its role in that domain was progressively eroded by the relentless spread of drug resistance. However, the emergence of the global HIV/AIDS pandemic in the 1980s created a vast population of immunocompromised individuals who were exquisitely vulnerable to opportunistic pathogens like T. gondii. In this new context, pyrimethamine's potent activity against toxoplasmosis was not just rediscovered but elevated to a role of paramount importance. Thus, the drug's clinical value was paradoxically resurrected and redefined by a different global health crisis, shifting its primary application from a common tropical disease to a life-threatening complication of immunosuppression.

Historical and Current Role in Malaria

Pyrimethamine was originally developed to combat malaria and, for several decades, played a central role in global control efforts.[10] In its fixed-dose combination with sulfadoxine (SP), marketed as Fansidar, it was a first-line agent for both the treatment of acute uncomplicated malaria and for prophylaxis, particularly in regions with chloroquine-resistant

Plasmodium falciparum.[6]

However, the widespread and often indiscriminate use of SP, especially as monotherapy for treatment, exerted immense selective pressure on the parasite population. This led to the global emergence and dissemination of P. falciparum strains carrying mutations in both the dhfr and dhps genes, conferring high-level resistance to the combination.[6] As a result, SP is no longer effective for treating acute malaria in most parts of the world and is not recommended by the Centers for Disease Control and Prevention (CDC) or other international bodies for routine prophylaxis in travelers.[6]

Despite its failure for treatment, pyrimethamine retains a critical, albeit niche, role in malaria control through its use in Intermittent Preventive Treatment in pregnancy (IPTp). In many malaria-endemic areas of sub-Saharan Africa, the World Health Organization (WHO) recommends that pregnant women receive at least two to three curative doses of SP during their second and third trimesters.[21] This strategy has been shown in numerous clinical trials to significantly reduce the incidence of maternal anemia, placental parasitemia, and low birth weight, even in areas with moderate levels of SP resistance.[22] The continued recommendation of SP for IPTp represents a complex and pragmatic public health trade-off. While the drug may be failing for the treatment of symptomatic individuals, the unique immunological context of pregnancy and the prophylactic goal of suppressing parasite replication mean that it can still confer substantial benefit to the vulnerable mother-fetus dyad. This policy balances the clear, immediate benefits for maternal and infant health against the longer-term risk of contributing to the pool of drug-resistant parasites, illustrating a nuanced approach to drug deployment in resource-limited settings.

Off-Label Uses: Pneumocystis Pneumonia and Cystoisosporiasis

Beyond its primary indications, pyrimethamine serves as an important alternative agent for the management of other opportunistic protozoal infections, typically in situations where first-line therapies are contraindicated, not tolerated, or have failed.[7]

• Pneumocystis jirovecii Pneumonia (PCP): While trimethoprim-sulfamethoxazole (TMP-SMX) is the drug of choice for PCP, pyrimethamine in combination with dapsone is a recommended alternative regimen for both primary and secondary prophylaxis in HIV-infected adults and adolescents who cannot take TMP-SMX.[6]
• Cystoisosporiasis (formerly Isosporiasis): This intestinal infection, caused by Cystoisospora belli, can cause severe, chronic diarrhea in immunocompromised patients. Pyrimethamine is an effective alternative therapy for both acute treatment and secondary prophylaxis when TMP-SMX cannot be used.[6]

Synthesis of Clinical Trial Data

The available clinical trial evidence for pyrimethamine reinforces its established roles and highlights its use almost exclusively within combination regimens. An analysis of completed trials reveals several key themes.[32]

First, combination therapy is the universal standard of practice. Trials consistently investigate pyrimethamine alongside other agents, such as sulfadoxine, amodiaquine, or artesunate, reflecting the clinical understanding that monotherapy is obsolete due to resistance.[32]

Second, a significant body of research focuses on its role in chemoprevention, particularly in vulnerable populations. Multiple large-scale trials have evaluated its use in Seasonal Malaria Chemoprevention (SMC) programs for children (e.g., NCT03035305) and as Intermittent Preventive Treatment in both children (NCT00119132) and pregnant women (NCT00146783, NCT01669941).[33] These studies underscore the drug's enduring public health importance in high-transmission settings for protecting those at greatest risk of severe malaria.

Third, the trial landscape demonstrates the dynamic and evolving nature of anti-infective therapy. Several studies directly compare the efficacy of SP-based regimens against newer artemisinin-based combination therapies (ACTs), such as dihydroartemisinin-piperaquine (NCT01669941, NCT00941785).[34] This comparative research is essential for updating treatment guidelines and ensuring that the most effective interventions are deployed in the face of growing drug resistance.

Dosage, Administration, and Formulations

The clinical administration of pyrimethamine requires meticulous attention to dosing, which varies significantly based on the indication, the patient's age and weight, and their underlying immune status. The dosing regimens for toxoplasmosis are substantially higher than those historically used for malaria and approach the threshold for toxicity, a fact that underscores the drug's narrow therapeutic index.[37] This pharmacological property dictates the complex protocols for its use, including the mandatory co-administration of leucovorin to mitigate host toxicity. The entire clinical approach to pyrimethamine is structured around navigating the fine line between achieving therapeutic efficacy and inducing severe adverse effects.

Dosing Regimens by Indication and Patient Population

Pyrimethamine is available for oral administration as a 25 mg scored tablet.[7] The following table summarizes the recommended dosing regimens for its principal indications, compiled from guidelines issued by regulatory bodies and infectious disease societies. It is imperative to note that leucovorin (folinic acid) rescue is a required component of all toxoplasmosis treatment regimens.

Indication	Patient Population	Pyrimethamine Dose	Required Co-medication	Required Rescue Agent	Source(s)
Treatment of Toxoplasmosis	Adults (≥60 kg)	Loading: 200 mg once Maintenance: 75 mg once daily	Sulfadiazine 1.5 g q6h	Leucovorin 10–25 mg daily	29
	Adults (<60 kg)	Loading: 200 mg once Maintenance: 50 mg once daily	Sulfadiazine 1 g q6h	Leucovorin 10–25 mg daily	29
	Pediatrics (Acquired)	Loading: 2 mg/kg daily for 3 days (max 50 mg) Maintenance: 1 mg/kg once daily (max 25 mg)	Sulfadiazine 25–50 mg/kg q6h	Leucovorin 10–25 mg daily	29
Treatment of Congenital Toxoplasmosis	Neonates & Infants	Loading: 2 mg/kg daily for 2 days Maintenance: 1 mg/kg daily for 2–6 months, then 1 mg/kg 3 times/week for a total of 12 months	Sulfadiazine 50 mg/kg q12h	Leucovorin 10 mg with each dose	25
Secondary Prophylaxis of Toxoplasmosis	Adults	25–50 mg once daily	Sulfadiazine 2–4 g daily in 2–4 doses	Leucovorin 10–25 mg daily	29
	Pediatrics	1 mg/kg once daily (max 25 mg)	Sulfadiazine 42.5–60 mg/kg q12h	Leucovorin 5 mg every 3 days	29
Primary Prophylaxis of Toxoplasmosis	Adults	50–75 mg once weekly	Dapsone 50 mg daily or 200 mg weekly	Leucovorin 25 mg weekly	29
Prophylaxis of PCP	Adults	50–75 mg once weekly	Dapsone 50 mg daily or 200 mg weekly	Leucovorin 25 mg weekly	29

Administration Guidelines and Management of Gastrointestinal Effects

Pyrimethamine should be administered orally. The tablets are scored, allowing for dose adjustments.[7] While it can be taken with or without food, administration with meals is generally recommended to minimize the common gastrointestinal side effects of anorexia, nausea, and vomiting.[5] For pediatric patients or adults who are unable to swallow tablets, an extemporaneous oral suspension can be prepared by crushing the 25 mg tablets and mixing the powder with a suitable vehicle such as water or cherry syrup. The resulting suspension should be shaken well prior to each administration.[7]

Comprehensive Safety and Tolerability Profile

The safety profile of pyrimethamine is well-characterized and is dominated by dose-dependent toxicities that are a direct extension of its mechanism of action, as well as idiosyncratic hypersensitivity reactions that are often associated with concomitant sulfonamide use. Vigilant clinical and laboratory monitoring is essential for its safe use, particularly at the high doses required for toxoplasmosis.

Adverse Drug Reactions by System Organ Class

The adverse effects of pyrimethamine span multiple organ systems, with hematologic, dermatologic, and gastrointestinal reactions being the most prominent.[2]

• Hematologic Effects: The most significant and predictable dose-related toxicity is bone marrow suppression resulting from folate deficiency. This can manifest as megaloblastic anemia, leukopenia (low white blood cell count), neutropenia (low neutrophil count), thrombocytopenia (low platelet count), and in severe cases, pancytopenia (suppression of all blood cell lines).[2] These effects are the primary reason that leucovorin rescue is mandatory and that regular monitoring of complete blood counts (CBC), including platelet counts, is required, often as frequently as twice weekly during high-dose therapy.[18] This represents a classic example of on-target toxicity, where the adverse effect is a direct consequence of the drug's intended pharmacological action on the host. This mechanistic understanding allows for a rational and effective management strategy (leucovorin rescue), making the toxicity manageable with strict adherence to clinical protocols.
• Dermatologic Reactions: Skin reactions can range from mild, maculopapular rashes to rare but life-threatening severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and erythema multiforme.[2] These severe reactions are a form of idiosyncratic hypersensitivity and their risk is significantly amplified when pyrimethamine is used in combination with sulfonamides, which are independently associated with SCARs. The clinical guidance is unequivocal: pyrimethamine and the accompanying sulfonamide must be discontinued immediately at the first appearance of any skin rash, and the patient must seek urgent medical evaluation.[27]
• Gastrointestinal Effects: Anorexia (loss of appetite), nausea, and vomiting are common, particularly with the high doses used for toxoplasmosis.[2] Atrophic glossitis, characterized by a sore, red, and smooth tongue, can also occur as a sign of folate deficiency.[2]
• Cardiovascular Effects: Although less common, disorders of cardiac rhythm and arrhythmias have been reported, particularly in the context of high doses or overdose.[2]
• Neurological Effects: Common central nervous system effects include headache and dizziness. At high doses, more severe toxicities such as ataxia, tremors, and convulsions can occur.[39]
• Respiratory Effects: Rare cases of pulmonary eosinophilia, a condition involving the accumulation of eosinophils in the lungs, have been reported.[38]

Contraindications, Warnings, and Precautions

The use of pyrimethamine is strictly contraindicated in specific patient populations where the risk of severe harm is unacceptably high.

Contraindications:

• Patients with a known hypersensitivity to pyrimethamine or any of the excipients in the formulation.[2]
• Patients with documented megaloblastic anemia secondary to folate deficiency.[2] Administering a potent folate antagonist in this setting would severely exacerbate the underlying hematologic condition.

Warnings and Precautions:

• Folate Deficiency: The drug should be used with extreme caution in patients with conditions that predispose them to folate deficiency, such as malabsorption syndromes, alcoholism, or pregnancy. Concurrent administration of other drugs that affect folate levels, like phenytoin, also warrants caution.[5]
• Renal and Hepatic Impairment: Caution is advised when administering pyrimethamine to patients with impaired renal or hepatic function, as drug accumulation may occur.[5]
• Pregnancy and Lactation: Pyrimethamine is classified as Pregnancy Category C in the United States. It has demonstrated teratogenicity in animal studies at doses comparable to those used for human toxoplasmosis treatment.[17] It should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus. If its use is deemed necessary, concurrent administration of folinic acid is strongly recommended.[17] Its use as part of the SP regimen for IPTp during the second and third trimesters is generally considered to have a favorable safety profile regarding teratogenicity, as organogenesis is complete.[31] The drug is excreted in breast milk, and a decision should be made to either discontinue nursing or the drug.[17]
• Pediatric Safety: Accidental ingestion by infants and children can be fatal. The medication must be stored securely and kept out of the reach of children at all times.[27]

Clinically Significant Drug-Drug Interactions

Pyrimethamine is subject to numerous drug-drug interactions, primarily related to its mechanism of action (folate antagonism) and its effects on the metabolism and excretion of other drugs. The following table highlights the most clinically important interactions.

Interacting Drug / Class	Potential Effect	Clinical Management Recommendation	Source(s)
Antifolates (e.g., Methotrexate, Trimethoprim, Proguanil)	Additive folate antagonism, leading to an increased risk of bone marrow suppression (myelosuppression).	Avoid concomitant use when possible. If necessary, monitor blood counts closely. Discontinue pyrimethamine if signs of folate deficiency develop and administer leucovorin.	2
Other Myelosuppressive Agents (e.g., Zidovudine, Cytostatic agents)	Increased risk of bone marrow suppression.	Use with caution and monitor hematologic parameters frequently.	2
Sulfonamides (e.g., Sulfadiazine, Sulfamethoxazole)	Synergistic therapeutic effect, but also increased risk of myelosuppression and severe cutaneous adverse reactions (SJS/TEN).	This combination is used intentionally for therapeutic benefit. Monitor blood counts and for any sign of skin rash. Discontinue immediately if rash occurs.	2
Dapsone	Additive adverse hematologic effects, including increased risk of agranulocytosis and hemolytic reactions.	Monitor for adverse hematologic effects more frequently than usual. Use with caution in patients with G6PD deficiency.	7
Lorazepam	Reports of mild hepatotoxicity when administered concomitantly.	Monitor liver function tests.	2
QTc-Prolonging Agents (e.g., Artemether, certain antipsychotics)	Increased risk of QTc interval prolongation and potential for cardiac arrhythmias.	Avoid co-administration if possible. If necessary, monitor ECG.	4
Inhibitors of Drug Excretion/Metabolism (e.g., Acyclovir, Atorvastatin, Ciprofloxacin)	Pyrimethamine may decrease the excretion or metabolism of these drugs, potentially increasing their plasma concentrations and risk of toxicity.	Monitor for signs of toxicity of the co-administered drug. Dose adjustments may be necessary.	4

Historical Context and Socio-Economic Impact

Discovery, Development, and Evolving Role in Infectious Disease

Pyrimethamine was discovered in 1952 at the laboratories of Burroughs-Wellcome (a predecessor of GlaxoSmithKline) by a team that included the Nobel laureate Gertrude Elion.[9] Its development was a product of a rational drug design program aimed at creating antimalarial agents by targeting the parasite's folate metabolism. It came into medical use in 1953 and, alongside chloroquine, quickly became a vital tool in the post-World War II global campaigns to control and eradicate malaria.[8]

The early clinical experience with pyrimethamine, however, provided a crucial and sobering lesson in the dynamics of antimicrobial resistance. When used as a monotherapy, resistance in Plasmodium parasites emerged with alarming speed, often within a year of its introduction in a region.[8] This rapid failure drove the development of combination therapies. The fixed-dose combination of pyrimethamine with the long-acting sulfonamide sulfadoxine was introduced in 1967 under the brand name Fansidar, establishing a new paradigm for antimalarial treatment aimed at delaying resistance.[8] For decades, this combination remained a key therapy until resistance to it also became widespread.

Case Study: The Daraprim Pricing Controversy and its Aftermath

In the 21st century, the story of pyrimethamine took a dramatic and unexpected turn, transforming it from a well-established, low-cost generic drug into a symbol of corporate greed and a flashpoint in the debate over pharmaceutical pricing in the United States.

The controversy began in 2010 when GlaxoSmithKline sold the U.S. marketing rights for Daraprim, which had previously sold for about $1.00 per pill, to CorePharma. The price was subsequently increased to $13.50 per pill.[42] The situation escalated dramatically in August 2015, when a newly formed company, Turing Pharmaceuticals, led by its CEO, former hedge fund manager Martin Shkreli, acquired the rights to the drug. Immediately following the acquisition, Turing implemented an unprecedented price increase, raising the list price of a single Daraprim tablet from $13.50 to $750—an increase of more than 5,000%.[42] This action instantly elevated the cost of a standard course of treatment for toxoplasmosis from a manageable sum to potentially hundreds of thousands of dollars per year for some patients.[42]

Turing's business strategy was not limited to the price hike alone. The company also implemented a "closed distribution" system, making Daraprim available only through a single specialty pharmacy, Walgreens.[10] This move effectively prevented potential generic competitors from legally obtaining the necessary quantities of the branded drug required to conduct the bioequivalence studies needed for FDA approval of a generic version. This tactic, while legal at the time, was designed to block market competition and maintain a monopoly on a 62-year-old, off-patent medication.[10]

The public and political reaction was swift and furious. The price hike was widely condemned as "price gouging" by medical organizations, including the Infectious Diseases Society of America (IDSA) and the HIV Medicine Association (HIVMA), as well as by patient advocacy groups and prominent politicians from both major parties.[10] Martin Shkreli became a figure of public vilification, dubbed the "pharma bro," a reputation he fueled with unapologetic and often inflammatory public statements and social media activity.[42] He defended the price increase by claiming that the profits were necessary to fund research and development for a new, improved toxoplasmosis drug and that patient assistance programs would ensure no patient would go without the medication—a claim that was quickly challenged by physicians who reported significant difficulties in accessing the drug for their patients.[42]

While the price increase itself was not illegal, Shkreli was later arrested, convicted, and sentenced to seven years in prison on unrelated federal charges of securities fraud stemming from his time as a hedge fund manager.[46] In a subsequent civil lawsuit brought by the Federal Trade Commission and several states, Shkreli was ordered in 2022 to return $64.6 million in profits from Daraprim and was banned from the pharmaceutical industry for life.[47]

The Daraprim scandal served as a powerful catalyst, exposing a systemic market failure within the U.S. healthcare system rather than just the actions of a single controversial executive. The case revealed how legal and regulatory loopholes could be exploited to create monopolies on old, essential generic drugs, leaving vulnerable patients and healthcare systems with no alternative but to pay exorbitant prices. This was not an isolated incident; other companies had employed similar strategies with different drugs, but the sheer scale of the Daraprim price hike and Shkreli's public persona brought the issue to the forefront of national attention.[44] The lasting impact of the controversy was the intense scrutiny it placed on these practices, which spurred policy discussions and ultimately contributed to the passage of legislation like the CREATES Act of 2019, designed to prevent such tactics and facilitate more timely generic drug entry.[46]

Date	Event	Significance
1953	Daraprim (pyrimethamine) first comes into medical use.	A key, low-cost antiprotozoal drug becomes available.
2010	GlaxoSmithKline sells U.S. marketing rights to CorePharma.	The drug leaves its original developer. The price increases from ~$1 to $13.50 per pill.
Aug 2015	Turing Pharmaceuticals, led by CEO Martin Shkreli, acquires the rights to Daraprim.	Sets the stage for the major pricing controversy.
Sep 2015	Turing raises the price of Daraprim from $13.50 to $750 per pill (>5,000% increase).	The action sparks immediate and widespread public, medical, and political outrage.
Late 2015	Turing implements a "closed distribution" system for Daraprim.	This tactic restricts access and hinders potential generic competitors.
Dec 2015	Martin Shkreli is arrested on unrelated federal securities fraud charges.	The legal troubles of the CEO become intertwined with the pricing scandal.
2018	Shkreli is sentenced to seven years in prison for securities fraud.	While not for the price hike, the conviction removes him from the industry. The price of Daraprim remains high.
Feb 2020	The FDA approves the first generic version of pyrimethamine.	This introduces market competition, the primary mechanism for reducing the drug's price.
Jan 2022	A federal court orders Shkreli to return $64.6 million in profits and bans him from the pharmaceutical industry for life.	A civil judgment directly addresses the anti-competitive practices related to Daraprim.

The Modern Commercial Landscape: Brand Names, Manufacturers, and Generic Availability

Today, pyrimethamine is available in the United States under the brand name Daraprim, which is marketed by Tilde Sciences.[50] The combination product with sulfadoxine, Fansidar, is no longer commercially available in the U.S. but may be used elsewhere.[7]

The true resolution to the pricing crisis created by Turing Pharmaceuticals was not public pressure or the downfall of its CEO, but the eventual restoration of market competition. For years after the scandal broke, the price of Daraprim remained at the inflated $750 level, as public shaming alone proved insufficient to force a significant and sustained price reduction.[45] The fundamental solution arrived in February 2020, when the FDA approved the first generic pyrimethamine tablets.[9] This pivotal regulatory action opened the door for competition, which is the most effective and durable mechanism for driving down the prices of off-patent drugs. Several generic manufacturers, including Aurobindo Pharma, Sanaluz, and Teva Pharmaceuticals, now market 25 mg pyrimethamine tablets, providing affordable alternatives and ensuring a more stable supply of this essential medicine.[50]

Conclusion: An Integrated Perspective on Pyrimethamine

The story of pyrimethamine is a multifaceted narrative that extends far beyond its chemical structure and pharmacological profile. It is a testament to the power of rational drug design, born from the mid-20th century quest to conquer malaria, and its journey reflects the dynamic and often unpredictable evolution of infectious diseases and their treatment. Its mechanism of action as a selective dihydrofolate reductase inhibitor is a textbook example of targeting a pathogen's unique metabolic needs, yet this very mechanism dictates its primary toxicity and necessitates a complex but elegant clinical protocol involving combination therapy and host rescue.

Clinically, pyrimethamine has undergone a profound strategic repositioning. Once a frontline antimalarial, its utility was decimated by the inexorable march of drug resistance—a cautionary tale that has shaped modern anti-infective strategies. Yet, it was given a new and vital purpose by the HIV/AIDS pandemic, becoming an indispensable, life-saving agent for the treatment and prevention of toxoplasmosis in the immunocompromised. Its continued, targeted use for intermittent preventive therapy in pregnancy in malaria-endemic regions further highlights its adaptability and the nuanced, risk-benefit calculations that define modern public health policy.

Finally, pyrimethamine's unintended legacy is that of a socio-economic case study. The Daraprim pricing scandal of 2015 thrust this decades-old drug into the global spotlight, making it a symbol of the ethical failings and systemic vulnerabilities within the pharmaceutical market. The controversy demonstrated that while moral outrage can catalyze debate, the most effective and sustainable solutions to ensuring access to essential medicines lie in robust regulatory frameworks that foster and protect market competition. From a laboratory breakthrough to a public health tool, and ultimately to a catalyst for policy reform, the comprehensive story of pyrimethamine serves as a powerful illustration of the intricate and enduring interplay between science, medicine, and society.

Works cited

1. Pyrimethamine 58-14-0 | TCI AMERICA, accessed August 26, 2025, https://www.tcichemicals.com/US/en/p/P2037
2. Pyrimethamine - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed August 26, 2025, https://www.pediatriconcall.com/drugs/pyrimethamine/914
3. Pyrimethamine | C12H13ClN4 | CID 4993 - PubChem, accessed August 26, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Pyrimethamine
4. Pyrimethamine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 26, 2025, https://go.drugbank.com/drugs/DB00205
5. Pyrimethamine (Daraprim) Tablets: Uses & Side Effects - Cleveland Clinic, accessed August 26, 2025, https://my.clevelandclinic.org/health/drugs/18308-pyrimethamine-tablets
6. Subject: Pyrimethamine (Daraprim) - Medical Coverage Guideline - Florida Blue, accessed August 26, 2025, https://mcgs.bcbsfl.com/MCG?mcgId=09-J2000-48&pv=false
7. Pyrimethamine Monograph for Professionals - Drugs.com, accessed August 26, 2025, https://www.drugs.com/monograph/pyrimethamine.html
8. History of antimalarial drugs - Medicines for Malaria Venture, accessed August 26, 2025, https://www.mmv.org/malaria-medicines/history-antimalarials-drugs
9. en.wikipedia.org, accessed August 26, 2025, https://en.wikipedia.org/wiki/Pyrimethamine#:~:text=Pyrimethamine%20was%20discovered%20in%201952,United%20States%20in%20February%202020.
10. Pyrimethamine - Wikipedia, accessed August 26, 2025, https://en.wikipedia.org/wiki/Pyrimethamine
11. Pyrimethamine | CAS 58-14-0 | SCBT - Santa Cruz Biotechnology, accessed August 26, 2025, https://www.scbt.com/p/pyrimethamine-58-14-0
12. Pyrimethamine | 58-14-0 - ChemicalBook, accessed August 26, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8461315.htm
13. [Pyrimethamine (200 mg)] - CAS [58-14-0] - USP Store, accessed August 26, 2025, https://store.usp.org/product/1589007
14. What is the mechanism of Pyrimethamine? - Patsnap Synapse, accessed August 26, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-pyrimethamine
15. FANSIDAR brand of sulfadoxine and pyrimethamine TABLETS Rx only WARNING: FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF FANSID - accessdata.fda.gov, accessed August 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18557slr015_fansidar_lbl.pdf
16. Plasma concentrations of pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data - World Health Organization (WHO), accessed August 26, 2025, https://apps.who.int/iris/bitstream/handle/10665/264803/PMC2536029.pdf?sequence=1&isAllowed=y
17. Pyrimethamine | Drug Lookup | Pediatric Care Online - AAP Publications, accessed August 26, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5360/Pyrimethamine
18. pyrimethamine, accessed August 26, 2025, https://www.glowm.com/resources/glowm/cd/pages/drugs/p077.html
19. (PDF) Population pharmacokinetics of pyrimethamine and ..., accessed August 26, 2025, https://www.researchgate.net/publication/8553839_Population_pharmacokinetics_of_pyrimethamine_and_sulfadoxine_in_children_with_congenital_toxoplasmosis
20. Pharmacology Pharmacokinetics of Sulfadoxine and Pyrimethamine after Fansidar® Administration in Man - Karger Publishers, accessed August 26, 2025, https://www.karger.com/Article/Pdf/238499
21. Pharmacokinetics of Sulfadoxine-Pyrimethamine in HIV-Infected and Uninfected Pregnant Women in Western Kenya | The Journal of Infectious Diseases | Oxford Academic, accessed August 26, 2025, https://academic.oup.com/jid/article/196/9/1403/2192091
22. Pyrimethamine – Knowledge and References - Taylor & Francis, accessed August 26, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Pyrimethamine/
23. Pharmacokinetic Properties of Sulfadoxine-Pyrimethamine in Pregnant Women | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed August 26, 2025, https://journals.asm.org/doi/10.1128/aac.00335-09
24. Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria - ASM Journals, accessed August 26, 2025, https://journals.asm.org/doi/10.1128/aac.01370-17
25. Pyrimethamine: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 26, 2025, https://www.rxlist.com/pyrimethamine/generic-drug.htm
26. Pharmacy Medical Necessity Guidelines: - Daraprim (pyrimethamine) - Point32Health, accessed August 26, 2025, https://www.point32health.org/provider/wp-content/uploads/sites/2/2024/01/Daraprim-pyrimethamine-comm-pmng.pdf
27. Welcome to DARAPRIM® Direct - For Patients | DARAPRIM® (pyrimethamine) 25mg tablets, accessed August 26, 2025, https://www.daraprimdirect.com/
28. PYRIMETHAMINE oral - MSF Medical Guidelines, accessed August 26, 2025, https://medicalguidelines.msf.org/en/viewport/EssDr/english/pyrimethamine-oral-16684546.html
29. Pyrimethamine Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 26, 2025, https://www.drugs.com/dosage/pyrimethamine.html
30. Sulfadoxine/pyrimethamine - Wikipedia, accessed August 26, 2025, https://en.wikipedia.org/wiki/Sulfadoxine/pyrimethamine
31. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment - PubMed, accessed August 26, 2025, https://pubmed.ncbi.nlm.nih.gov/17536875/
32. Pyrimethamine Completed Phase N/A Trials for Weight, Birth / Malaria in Pregnancy / Anemia Treatment - DrugBank, accessed August 26, 2025, https://go.drugbank.com/drugs/DB00205/clinical_trials?conditions=DBCOND0020261%2CDBCOND0031013%2CDBCOND0143987&purpose=treatment&status=completed
33. Pyrimethamine Completed Phase Trials for Malaria Prevention | DrugBank Online, accessed August 26, 2025, https://go.drugbank.com/drugs/DB00205/clinical_trials?conditions=DBCOND0007188&phase=&purpose=prevention&status=completed
34. Pregnancy Completed Phase 4 Trials for Pyrimethamine (DB00205) | DrugBank Online, accessed August 26, 2025, https://go.drugbank.com/indications/DBCOND0018394/clinical_trials/DB00205?phase=4&status=completed
35. Pyrimethamine Completed Phase 2 / 3 Trials for Malaria Prevention | DrugBank Online, accessed August 26, 2025, https://go.drugbank.com/drugs/DB00205/clinical_trials?conditions=DBCOND0007188&phase=2%2C3&purpose=prevention&status=completed
36. Pyrimethamine Completed Phase 4 Trials for Malaria Treatment | DrugBank Online, accessed August 26, 2025, https://go.drugbank.com/drugs/DB00205/clinical_trials?conditions=DBCOND0007188&phase=4&purpose=treatment&status=completed
37. DARAPRIM - accessdata.fda.gov, accessed August 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/8578s15lbl.pdf
38. Pyrimethamine (Daraprim): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed August 26, 2025, https://www.webmd.com/drugs/2/drug-634/daraprim-oral/details
39. Pyrimethamine Side Effects: Common, Severe, Long Term, accessed August 26, 2025, https://www.drugs.com/sfx/pyrimethamine-side-effects.html
40. What are the side effects of Pyrimethamine? - Patsnap Synapse, accessed August 26, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-pyrimethamine
41. Reference ID: 4114489 This label may not be the latest approved by ..., accessed August 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/008578s020lbl.pdf
42. Get Rich Quick With Old Generic Drugs! The Pyrimethamine Pricing ..., accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4685150/
43. (PDF) Get Rich Quick With Old Generic Drugs! The Pyrimethamine Pricing Scandal, accessed August 26, 2025, https://www.researchgate.net/publication/283790712_Get_Rich_Quick_With_Old_Generic_Drugs_The_Pyrimethamine_Pricing_Scandal
44. Daraprim and Predatory Pricing: Martin Shkreli's 5000% Hike - Law ..., accessed August 26, 2025, https://law.stanford.edu/2015/10/05/daraprim-and-drug-pricing/
45. 'Pharma Bro' Shkreli Is In Prison, But Daraprim's Price Is Still High, accessed August 26, 2025, https://kffhealthnews.org/news/for-shame-pharma-bro-shkreli-is-in-prison-but-daraprims-price-is-still-high/
46. How Martin Shkreli's Price Gouging Scandal Led to Stricter Laws for Drug Pricing, accessed August 26, 2025, https://www.investopedia.com/martin-shkreli-s-price-gouging-scandal-11725521
47. Martin Shkreli: Man who made huge profits by inflating price of life-saving drug ordered to return £47m - Sky News, accessed August 26, 2025, https://news.sky.com/story/martin-shkreli-man-who-made-huge-profits-by-inflating-price-of-life-saving-drug-ordered-to-return-47m-12516161
48. Daraprim Price Hike - Ethics Unwrapped - University of Texas at Austin, accessed August 26, 2025, https://ethicsunwrapped.utexas.edu/video/daraprim-price-hike
49. Martin Shkreli Returns as Drug Prices Continue to Rise - Viterbi Conversations in Ethics, accessed August 26, 2025, https://vce.usc.edu/weekly-news-profile/martin-shkreli-returns-as-drug-prices-continue-to-rise/
50. Generic Daraprim Availability - Drugs.com, accessed August 26, 2025, https://www.drugs.com/availability/generic-daraprim.html
51. Generic PYRIMETHAMINE INN equivalents, drug patent and freedom to operate, accessed August 26, 2025, https://www.drugpatentwatch.com/p/generic-api/PYRIMETHAMINE